Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1165]
News [3108]
Articles [128]
Editorials [5]
Conferences [139]
elearning [16]
Lurbinectedin in PARP resistant breast cancer
Dr Cristina Cruz - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Lurbinectedin in PARP resistant breast cancer ( Dr Cristina Cruz - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )
10 Oct 2016
Lurbinectedin in BRCA 1/2 breast cancer
Dr Judith Balmaña - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Lurbinectedin in BRCA 1/2 breast cancer ( Dr Judith Balmaña - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )
10 Oct 2016
Olaparib and paclitaxel for 2nd line gastric cancer therapy
Dr Yung-Jue Bang - Seoul National University, Seoul, South Korea
Olaparib and paclitaxel for 2nd line gastric cancer therapy ( Dr Yung-Jue Bang - Seoul National University, Seoul, South Korea )
10 Oct 2016
Comment: Ribociclib for breast cancer
Dr Evandro De Azambuja - ‎Jules Bordet Institute, Brussels, Belgium
Comment: Ribociclib for breast cancer ( Dr Evandro De Azambuja - ‎Jules Bordet Institute, Brussels, Belgium )
10 Oct 2016
Treating CNS metastases from breast cancer with a peptide/paclitaxel conjugate
Prof Shou-Ching Tang - Augusta University Cancer Center, Augusta USA
Treating CNS metastases from breast cancer with a peptide/paclitaxel conjugate ( Prof Shou-Ching Tang - Augusta University Cancer Center, Augusta USA )
10 Oct 2016
Highlights of ESMO 2016
Dr Andrés Cervantes - ESMO 2016 Scientific Chair
Highlights of ESMO 2016 ( Dr Andrés Cervantes - ESMO 2016 Scientific Chair )
10 Oct 2016
Cabozantinib over sunitinib for metastatic renal cell carcinoma
Dr Toni Choueiri - Dana Farber Cancer Institute, Boston, USA
Cabozantinib over sunitinib for metastatic renal cell carcinoma ( Dr Toni Choueiri - Dana Farber Cancer Institute, Boston, USA )
10 Oct 2016
Ceritinib following crizotinib relapse for ALK positive NSCLC
Dr Giorgio Scagliotti - University of Turin, Turin, Italy
Ceritinib following crizotinib relapse for ALK positive NSCLC ( Dr Giorgio Scagliotti - University of Turin, Turin, Italy )
9 Oct 2016
Significant survival gains with atezolizumab for NSCLC
Dr Fabrice Barlesi - Hôpital Nord, Marseille, France
Significant survival gains with atezolizumab for NSCLC ( Dr Fabrice Barlesi - Hôpital Nord, Marseille, France )
9 Oct 2016
Pembrolizumab new option for firstline treatment of advanced lung cancer with...
Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany
Pembrolizumab new option for firstline treatment of advanced lung cancer with high PDL-1 expression ( Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany )
9 Oct 2016
Pembrolizumab plus chemo as firstline therapy for NSCLC
Dr Corey Langer - University of Pennsylvania, Philadelphia, USA
Pembrolizumab plus chemo as firstline therapy for NSCLC ( Dr Corey Langer - University of Pennsylvania, Philadelphia, USA )
9 Oct 2016
KRAS in the clinic and conference
Dr Ana Vivancos - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
KRAS in the clinic and conference ( Dr Ana Vivancos - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )
9 Oct 2016

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation